一次情報の記録
FDAは、REMS関連の情報要求に対するAgiosの回答を主要な修正と分類した後、鎌状赤血球症におけるmitapivat sNDAのPDUFA目標日を3ヶ月延長して2027年2月1日としました。同社は発売準備を整えており、FDAとのラベル表示に関する協議を継続しています。
EX-99.1 2 agio-110526xfyxex991earnin.htm EX-99.1 文書 Exhibit 99.1 Agios Reports Third Quarter 2026 Financial Results and Provides Business Update • Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 • Strong U.S. demand for AQVESME in thalassemia continues, with 619 cumulative prescriptions with completed start forms from REMS-certified physicians, plus 48 additional prescriptions with start forms in process as of September 30, 2026 • New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA • 14 abstracts accepted at ASH 2026, including new clinical data for m